BHVN vs. RDY, SRPT, CTLT, ELAN, ROIV, INSM, ASND, LEGN, CERE, and ITCI
Should you be buying Biohaven stock or one of its competitors? The main competitors of Biohaven include Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Catalent (CTLT), Elanco Animal Health (ELAN), Roivant Sciences (ROIV), Insmed (INSM), Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), Cerevel Therapeutics (CERE), and Intra-Cellular Therapies (ITCI). These companies are all part of the "pharmaceutical preparations" industry.
Biohaven (NYSE:BHVN) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings, profitability and community ranking.
Dr. Reddy's Laboratories has higher revenue and earnings than Biohaven. Biohaven is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.
Biohaven has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500.
Dr. Reddy's Laboratories has a net margin of 19.97% compared to Biohaven's net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 21.27% beat Biohaven's return on equity.
Biohaven currently has a consensus target price of $55.00, suggesting a potential upside of 63.50%. Dr. Reddy's Laboratories has a consensus target price of $81.00, suggesting a potential upside of 13.51%. Given Biohaven's stronger consensus rating and higher probable upside, analysts clearly believe Biohaven is more favorable than Dr. Reddy's Laboratories.
Biohaven received 56 more outperform votes than Dr. Reddy's Laboratories when rated by MarketBeat users. Likewise, 65.55% of users gave Biohaven an outperform vote while only 59.25% of users gave Dr. Reddy's Laboratories an outperform vote.
In the previous week, Biohaven had 2 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 5 mentions for Biohaven and 3 mentions for Dr. Reddy's Laboratories. Biohaven's average media sentiment score of 1.19 beat Dr. Reddy's Laboratories' score of 0.84 indicating that Biohaven is being referred to more favorably in the media.
88.8% of Biohaven shares are owned by institutional investors. Comparatively, 14.0% of Dr. Reddy's Laboratories shares are owned by institutional investors. 16.0% of Biohaven shares are owned by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Biohaven beats Dr. Reddy's Laboratories on 11 of the 18 factors compared between the two stocks.
Get Biohaven News Delivered to You Automatically
Sign up to receive the latest news and ratings for BHVN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BHVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biohaven Competitors List
Related Companies and Tools
